vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and IMAX CORP (IMAX). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $125.2M, roughly 2.0× IMAX CORP). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 0.5%, a 10.6% gap on every dollar of revenue. On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs 29.6%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $28.0M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 25.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
ANIP vs IMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $125.2M |
| Net Profit | $27.5M | $637.0K |
| Gross Margin | — | 57.6% |
| Operating Margin | 14.1% | 19.3% |
| Net Margin | 11.1% | 0.5% |
| Revenue YoY | 29.6% | 35.1% |
| Net Profit YoY | 367.5% | -88.0% |
| EPS (diluted) | $1.14 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $125.2M | ||
| Q3 25 | $227.8M | $106.7M | ||
| Q2 25 | $211.4M | $91.7M | ||
| Q1 25 | $197.1M | $86.7M | ||
| Q4 24 | $190.6M | $92.7M | ||
| Q3 24 | $148.3M | $91.5M | ||
| Q2 24 | $138.0M | $89.0M | ||
| Q1 24 | $137.4M | $79.1M |
| Q4 25 | $27.5M | $637.0K | ||
| Q3 25 | $26.6M | $20.7M | ||
| Q2 25 | $8.5M | $11.3M | ||
| Q1 25 | $15.7M | $2.3M | ||
| Q4 24 | $-10.3M | $5.3M | ||
| Q3 24 | $-24.2M | $13.9M | ||
| Q2 24 | $-2.3M | $3.6M | ||
| Q1 24 | $18.2M | $3.3M |
| Q4 25 | — | 57.6% | ||
| Q3 25 | — | 63.1% | ||
| Q2 25 | — | 58.5% | ||
| Q1 25 | — | 61.4% | ||
| Q4 24 | — | 52.2% | ||
| Q3 24 | — | 55.8% | ||
| Q2 24 | — | 49.4% | ||
| Q1 24 | — | 59.3% |
| Q4 25 | 14.1% | 19.3% | ||
| Q3 25 | 15.9% | 27.2% | ||
| Q2 25 | 6.6% | 15.6% | ||
| Q1 25 | 13.3% | 19.3% | ||
| Q4 24 | -2.3% | 10.3% | ||
| Q3 24 | -13.8% | 21.2% | ||
| Q2 24 | 3.7% | 3.2% | ||
| Q1 24 | 14.8% | 15.3% |
| Q4 25 | 11.1% | 0.5% | ||
| Q3 25 | 11.7% | 19.4% | ||
| Q2 25 | 4.0% | 12.3% | ||
| Q1 25 | 8.0% | 2.7% | ||
| Q4 24 | -5.4% | 5.7% | ||
| Q3 24 | -16.3% | 15.2% | ||
| Q2 24 | -1.7% | 4.0% | ||
| Q1 24 | 13.2% | 4.1% |
| Q4 25 | $1.14 | $0.02 | ||
| Q3 25 | $1.13 | $0.37 | ||
| Q2 25 | $0.36 | $0.20 | ||
| Q1 25 | $0.69 | $0.04 | ||
| Q4 24 | $-0.45 | $0.09 | ||
| Q3 24 | $-1.27 | $0.26 | ||
| Q2 24 | $-0.14 | $0.07 | ||
| Q1 24 | $0.82 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $151.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $337.9M |
| Total Assets | $1.4B | $894.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $151.2M | ||
| Q3 25 | $262.6M | $143.1M | ||
| Q2 25 | $217.8M | $109.3M | ||
| Q1 25 | $149.8M | $97.1M | ||
| Q4 24 | $144.9M | $100.6M | ||
| Q3 24 | $145.0M | $104.5M | ||
| Q2 24 | $240.1M | $91.6M | ||
| Q1 24 | $228.6M | $81.0M |
| Q4 25 | $540.7M | $337.9M | ||
| Q3 25 | $505.8M | $349.5M | ||
| Q2 25 | $436.8M | $320.4M | ||
| Q1 25 | $418.6M | $299.5M | ||
| Q4 24 | $403.7M | $299.5M | ||
| Q3 24 | $405.9M | $289.4M | ||
| Q2 24 | $455.8M | $267.2M | ||
| Q1 24 | $452.0M | $258.8M |
| Q4 25 | $1.4B | $894.0M | ||
| Q3 25 | $1.4B | $889.6M | ||
| Q2 25 | $1.3B | $868.6M | ||
| Q1 25 | $1.3B | $848.3M | ||
| Q4 24 | $1.3B | $830.4M | ||
| Q3 24 | $1.3B | $847.6M | ||
| Q2 24 | $920.8M | $827.4M | ||
| Q1 24 | $914.5M | $824.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $29.4M |
| Free Cash FlowOCF − Capex | $29.1M | $28.0M |
| FCF MarginFCF / Revenue | 11.8% | 22.3% |
| Capex IntensityCapex / Revenue | 0.5% | 1.1% |
| Cash ConversionOCF / Net Profit | 1.10× | 46.11× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $118.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $29.4M | ||
| Q3 25 | $44.1M | $67.5M | ||
| Q2 25 | $75.8M | $23.2M | ||
| Q1 25 | $35.0M | $7.0M | ||
| Q4 24 | $15.9M | $11.5M | ||
| Q3 24 | $12.5M | $35.3M | ||
| Q2 24 | $17.4M | $35.0M | ||
| Q1 24 | $18.3M | $-11.0M |
| Q4 25 | $29.1M | $28.0M | ||
| Q3 25 | $38.0M | $64.8M | ||
| Q2 25 | $71.8M | $20.9M | ||
| Q1 25 | $32.5M | $5.3M | ||
| Q4 24 | $13.5M | $6.9M | ||
| Q3 24 | $7.7M | $34.2M | ||
| Q2 24 | $13.0M | $33.5M | ||
| Q1 24 | $13.7M | $-12.1M |
| Q4 25 | 11.8% | 22.3% | ||
| Q3 25 | 16.7% | 60.7% | ||
| Q2 25 | 34.0% | 22.8% | ||
| Q1 25 | 16.5% | 6.1% | ||
| Q4 24 | 7.1% | 7.4% | ||
| Q3 24 | 5.2% | 37.3% | ||
| Q2 24 | 9.4% | 37.6% | ||
| Q1 24 | 10.0% | -15.3% |
| Q4 25 | 0.5% | 1.1% | ||
| Q3 25 | 2.7% | 2.6% | ||
| Q2 25 | 1.9% | 2.6% | ||
| Q1 25 | 1.3% | 1.9% | ||
| Q4 24 | 1.3% | 5.0% | ||
| Q3 24 | 3.2% | 1.2% | ||
| Q2 24 | 3.2% | 1.8% | ||
| Q1 24 | 3.3% | 1.4% |
| Q4 25 | 1.10× | 46.11× | ||
| Q3 25 | 1.66× | 3.27× | ||
| Q2 25 | 8.87× | 2.06× | ||
| Q1 25 | 2.23× | 2.99× | ||
| Q4 24 | — | 2.16× | ||
| Q3 24 | — | 2.54× | ||
| Q2 24 | — | 9.78× | ||
| Q1 24 | 1.00× | -3.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
